Status:
UNKNOWN
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This study characterizes cardiac events following standard of care chimeric antigen receptor T cell therapy in patients with aggressive B-Cell Lymphoma that has come back (relapsed) or does not respon...
Detailed Description
PRIMARY OBJECTIVE: I. To characterize cardiac events following standard of Care (SOC) chimeric antigen receptor T (CAR-T) cell therapy in adult patients with relapsed/refractory aggressive B-cell lym...
Eligibility Criteria
Inclusion
- Adults (\>= 18 years) with a diagnosis of aggressive B-cell lymphoma (such as transformed follicular lymphoma, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and high-grade B-cell lymphoma), who received standard of care (SOC) chimeric antigen receptor T (CAR-T) cell therapy at MD Anderson Cancer Center
Exclusion
- None
Key Trial Info
Start Date :
April 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 30 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04870853
Start Date
April 2 2020
End Date
January 30 2025
Last Update
November 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030